- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:02 | Medicus Pharma Ltd: Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 280 | ACCESS Newswire | Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect and Teverelix Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion... ► Artikel lesen | |
| Mi | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 03.08. | Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev | 2 | Investing.com | ||
| 03.08. | Medicus Pharma Ltd: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom | 287 | GlobeNewswire (Europe) | PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 31.07. | Medicus Pharma receives UAE approval for endometriosis study | 1 | Investing.com | ||
| 31.07. | Medicus Pharma Ltd: Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix in Women with Endometriosis | 3 | GlobeNewswire (USA) | ||
| 31.07. | EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi | 1 | Benzinga.com | ||
| 27.07. | FDA clears Medicus Pharma Gorlin Syndrome study to proceed | 5 | Investing.com | ||
| 27.07. | FDA gibt grünes Licht für Studie von Medicus Pharma zum Gorlin-Syndrom | 9 | Investing.com Deutsch | ||
| 27.07. | Medicus Pharma Ltd: Medicus Pharma Receives FDA "Study May Proceed" Letter for NDA-Enabling Registrational SkinJect Study in Patients with Gorlin Syndrome | 332 | GlobeNewswire (Europe) | PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 25.07. | New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings | 1.070 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / July 25, 2026 / New to The Street, one of America's longest-running sponsored business television brands, today announced the broadcast of its latest episode, airing... ► Artikel lesen | |
| 16.07. | Medicus Pharma Ltd: Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention | 245 | GlobeNewswire (Europe) | PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 04.07. | New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell's Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group | 4.611 | ACCESS Newswire | Honoring Economic Freedom and American Capitalism Through Television That Connects Markets, Entrepreneurs, and InvestorsNational Sponsored Broadcast Includes Executive Interviews and Television Commercial... ► Artikel lesen | |
| 22.06. | Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026 | 9 | Benzinga.com | ||
| 22.06. | Medicus Pharma Ltd: Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 | 7 | GlobeNewswire (USA) | ||
| 15.06. | Medicus Pharma Ltd: Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome | 7 | GlobeNewswire (USA) | ||
| 11.06. | Medicus Pharma submits IND application for endometriosis trial | 3 | Investing.com | ||
| 11.06. | Medicus Pharma Ltd: Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program | 252 | GlobeNewswire (Europe) | PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 08.06. | Medicus Pharma Ltd: Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission | 642 | GlobeNewswire (Europe) | PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 03.06. | Medicus Pharma Ltd: Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome | 358 | GlobeNewswire (Europe) | PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen |
1 2 3 4 5 Weiter >>
85 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,810 | -1,04 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer nach Zahlen zum zweiten Quartal mit einem Kursziel von 34 US-Dollar auf "Buy" belassen. Der Pharmakonzern habe mit... ► Artikel lesen | |
| GILEAD SCIENCES | 117,76 | +0,12 % | Gilead Sciences und GS-1179: Riesige Milliardenumsätze mit neuer Herpes-Franchise? | Noch schweigt Gilead offiziell zu seiner langfristigen Strategie im Herpesmarkt. Doch zwischen den Zeilen des aktuellen Pipeline-Updates im Rahmen der Quartalszahlen zeichnet sich erstmals ein Bild... ► Artikel lesen | |
| ELI LILLY | 1.059,40 | +0,68 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 455,55 | -0,72 % | RBC Capital reiterates Vertex stock rating on pipeline outlook | ||
| INNOCAN PHARMA | 1,305 | -7,12 % | Innocan Pharma Corporation: Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust | Milestone underscores strong consumer confidence, exceptional product quality, and the Company's expanding presence in the U.S. consumer wellness marketHERZLIYA, Israel and CALGARY, Alberta... ► Artikel lesen | |
| EYEPOINT | 11,800 | +4,42 % | EyePoint, Inc. - 10-Q, Quarterly Report | ||
| LIGAND PHARMACEUTICALS | 260,00 | +4,00 % | LIGAND PHARMACEUTICALS INC - 10-Q, Quarterly Report | ||
| JAZZ PHARMACEUTICALS | 215,70 | +0,42 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio | Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
Leverages Jazz development expertise and commercial strength in... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,700 | -3,39 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| UNITED THERAPEUTICS | 445,30 | -0,22 % | United Therapeutics Corp Bottom Line Climbs In Q2 | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) announced a profit for its second quarter that Increased, from the same period last yearThe company's earnings totaled $333.0 million,... ► Artikel lesen | |
| OPKO HEALTH | 1,180 | -0,84 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health | Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| JAGUAR HEALTH | 0,761 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 | As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two commercialized... ► Artikel lesen | |
| ROYALTY PHARMA | 50,93 | +1,70 % | Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts |
WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 73,00 | -0,40 % | BridgeBio Pharma, Inc.: BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates | - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,338 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.